コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ngly influenced by fasting hyperglycemia and abdominal obesity.
2 fat and systemic inflammation in people with abdominal obesity.
3 ions, as well as coexistent hypertension and abdominal obesity.
4 s associations with body mass index (BMI) or abdominal obesity.
5 of the subjects were obese, and 94 (76%) had abdominal obesity.
6 eural networks that may lead toward ultimate abdominal obesity.
7 ors for coronary heart disease in women with abdominal obesity.
8 glyceride level, elevated glucose level, and abdominal obesity.
9 nt of the metabolic syndrome associated with abdominal obesity.
10 the metabolic abnormalities associated with abdominal obesity.
11 uring early fasting is blunted in women with abdominal obesity.
12 xpenditure, altered lipolysis, and increased abdominal obesity.
13 cardiovascular risk factors associated with abdominal obesity.
14 p to half of the association was mediated by abdominal obesity.
15 ratio can reveal new therapeutic targets for abdominal obesity.
16 in 5 adults worldwide with a normal BMI had abdominal obesity.
17 specially women and subjects with or without abdominal obesity.
18 ng smoking, old age at urine collection, and abdominal obesity.
19 protection from T2D but also with increased abdominal obesity.
20 togenic ectopic fat depots among adults with abdominal obesity.
21 ms underlying T2D risk stratification within abdominal obesity.
22 randomly assigned participants with moderate abdominal obesity.
23 dditional insight on genetic contribution to abdominal obesity.
24 intensity resulted in similar reductions in abdominal obesity.
25 postprandial lipid metabolism in humans with abdominal obesity.
26 d 2.24 (95%CI, 1.78-2.82), respectively, for abdominal obesity.
27 tion effect did not differ by general versus abdominal obesity.
28 overweight or obese and less likely to have abdominal obesity.
29 itions of equal energy deficit in women with abdominal obesity.
30 e models of genes predicted to be causal for abdominal obesity.
31 5% confidence interval (CI): 0.50, 0.69] and abdominal obesity (0.74; 95% CI: 0.66, 0.82), and a lowe
33 5.2) greater WC, and 3-fold greater odds of abdominal obesity (2.9; 1.6, 5.1) compared with women wh
34 mpared with participants in 2015, had higher abdominal obesity (389 participants [73.2%] vs 233 parti
35 valence of components in MetS was 57.75% for abdominal obesity, 44.05% for elevated blood pressure, 4
36 had the highest prevalence of normal-weight abdominal obesity (58.4%; 95% CI, 54.1%-62.6%), while Mo
37 rolled trial among 278 sedentary adults with abdominal obesity (75%) or dyslipidemia in an isolated w
39 ivin E as a potential therapeutic target for abdominal obesity, a phenotype linked to cardiometabolic
40 ) = 1.163; 95% CI = 1.023-1.323; p = 0.021), abdominal obesity (adjusted OR(gamma) = 1.173; 95% CI =
41 to higher WHRadjBMI predicts an increase in abdominal obesity after weight loss, whereas genetic pre
42 ve assessed the association between nuts and abdominal obesity, although an inverse association with
43 ferentiation of new adipocytes, resulting in abdominal obesity and a metabolic syndrome-like conditio
47 2.59) in subjects in the lowest quintiles of abdominal obesity and fasting hyperglycemia, respectivel
51 ndicates that women tended to have onsets of abdominal obesity and hypo-alpha-lipoproteinemia in youn
52 S variants and partitioned polygenic risk of abdominal obesity and inflammation to the SAT epigenome.
54 l design in which HIV-infected subjects with abdominal obesity and insulin resistance were randomized
55 which hsCRP is likely to be elevated, namely abdominal obesity and insulin resistance, provides a fra
57 lity exists, a negative relationship between abdominal obesity and insulin sensitivity was confirmed
59 s a potential interaction (P = 0.08) between abdominal obesity and low 25(OH)D concentrations that sh
61 ed adipogenesis and angiogenesis, leading to abdominal obesity and metabolic syndrome which were inhi
62 nutritional risk predicts the development of abdominal obesity and MetS during long-term follow-up in
63 ted prevalences of overweight or obesity and abdominal obesity and odds ratios with SUDAAN software (
64 efect in muscle aPKC is sufficient to induce abdominal obesity and other lipid abnormalities of the m
65 ad a 2- to 3-fold risk of the development of abdominal obesity and overall MetS during 12 y of follow
66 abolic pathways and networks contributing to abdominal obesity and overlapped with a macrophage-enric
67 id economic development and urban migration, abdominal obesity and related chronic diseases are likel
68 ized controlled trial, 92 men and women with abdominal obesity and relatively low HDL-cholesterol con
69 optimal exercise modality for reductions of abdominal obesity and risk factors for type 2 diabetes i
72 changes in body composition, involving both abdominal obesity and stavudine-induced peripheral lipoa
74 erences in the association between dynapenic abdominal obesity and the decline in physical performanc
76 mance is worse in individuals with dynapenic abdominal obesity and whether there are sex differences
79 ibutable risk percentage of overall obesity, abdominal obesity, and high FM for incident HF was highe
80 ibutable risk percentage of overall obesity, abdominal obesity, and high FM for incident HF was highe
81 conditions (diabetes, hypertension, obesity, abdominal obesity, and hypercholesterolemia), and access
84 ally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impai
85 s, including body mass index z-score (zBMI), abdominal obesity (AO), total cholesterol (TC), and trig
87 Effects on cardiorespiratory fitness and abdominal obesity are both likely to contribute to the i
95 r aim was to examine the association between abdominal obesity, as measured by the waist-to-hip ratio
96 as measured by body mass index, and that of abdominal obesity, as measured by waist-to-hip ratio, ha
98 nostic approaches vary but commonly focus on abdominal obesity (assessed using waist circumference),
99 ene, the transcription factor TBX15, and its abdominal obesity-associated deleterious missense varian
101 the metabolic syndrome: insulin resistance, abdominal obesity based on waist circumference, hypertri
103 uses of death and disability worldwide, with abdominal obesity being a major contributor to these con
104 studies, significant improvements in weight, abdominal obesity, blood pressure, and lipid profile wer
105 ssociations of BPA exposure with general and abdominal obesity, BPF or BPS, at current exposure level
107 acid glycine (Gly) is associated with intra-abdominal obesity, but the mechanism remains unclear.
108 Significant EAC risk factors included age, abdominal obesity, caffeine intake, and the presence of
110 the epidemic has leveled off, prevalence of abdominal obesity continues to rise, especially among ad
111 vide partial support for the hypothesis that abdominal obesity contributes to GERD, which may in turn
112 e identification and management of dynapenic abdominal obesity could be essential to avoiding the fir
115 e prevalence of overweight or obesity and of abdominal obesity decreased with increased snacking freq
118 istance (HOMA-IR) value greater than 2.2 and abdominal obesity (defined as waist circumference >88 cm
119 ies a substantial number of individuals with abdominal obesity despite BMI <30 kg/m(2), and may enhan
121 ages at onset of 5 cardiometabolic diseases: abdominal obesity, diabetes, hypertension, hypertriglyce
122 specific and only in men with a phenotype of abdominal obesity-diabetes, a positive link was observed
123 f metabolic syndrome include hyperglycaemia, abdominal obesity, dyslipidaemia, and high blood pressur
124 cludes insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia with high triglyceride a
125 risk factors, including insulin resistance, abdominal obesity, dyslipidemia, and hypertension, and i
126 were significant differences in measures of abdominal obesity, dyslipidemia, hyperinsulinemia, and t
127 concerning because South Asians show greater abdominal obesity, ectopic fat accumulation (particularl
129 g, and Blood Institute criteria and included abdominal obesity, elevated triglycerides, low high-dens
130 ), are especially common in: (i) adults with abdominal obesity, especially enlargement of visceral ad
131 , early type 2 diabetes mellitus, ubiquitous abdominal obesity, exposure to the world's highest level
132 estigate whether the increased risk of fetal abdominal obesity (FAO) is present in the older (>= 35 y
134 rameters, and lipid metabolism in males with abdominal obesity following two distinct interventions:
136 sms that uncouple the genetic inheritance of abdominal obesity from T2D risk have not yet been descri
137 yte DMRs and A compartments are enriched for abdominal obesity genome-wide association study (GWAS) v
139 , being divorced/widowed, alcohol intake and abdominal obesity had higher odds of HEPHA; higher educa
143 children and adults, particularly those with abdominal obesity, have an elevated serum triacylglycero
144 molecule biochemicals, dramatically improves abdominal obesity, hepatosteatosis, hypertriglyceridemia
145 me (MetS), a cluster of conditions including abdominal obesity, high blood pressure, and abnormal blo
148 2; 95% CI: 1.03, 4.77; P-trend = 0.032), and abdominal obesity (HRQ4vsQ1 = 2.68; 95% CI: 1.06, 6.79;
149 In individuals with type 2 diabetes with abdominal obesity, hyperfiltration is a risk factor for
150 3 or more of the following characteristics: abdominal obesity, hyperglycemia, hypertension, hypertri
152 of 4 out of 5 individual components of MetS (abdominal obesity, hypertriglyceridemia, low high-densit
153 diabetes later; men tended to have onsets of abdominal obesity, hypo-alpha-lipoproteinemia, and hyper
155 ociations of snacking with weight status and abdominal obesity in adolescents 12-18 y of age (n = 581
156 or instance, fruit consumption was linked to abdominal obesity in children (abdominal obesity vs. nor
158 and early-life nutritional status relate to abdominal obesity in men and women and to type 2 diabete
163 trend<0.001), and age adjusted prevalence of abdominal obesity increased from 54.5% (51.2% to 57.8%)
169 evealed that even though a high incidence of abdominal obesity is observed in females with SMS, they
171 a, low HDL cholesterol, hypertension, and/or abdominal obesity, is a risk factor for the development
173 strong interrelation between generalized and abdominal obesity leading to a mutually confounding effe
174 ts, independently, were associated with with abdominal obesity, low energy expenditure, and muscle we
176 hese results suggest that genetic effects on abdominal obesity may be more pronounced than those on g
177 The insulin resistance syndrome, including abdominal obesity, may constitute the intermediate link
180 o have CAD risk factors, but neither BMI nor abdominal obesity measures were significantly associated
181 /nonabdominal obesity (ND/NAO), nondynapenic/abdominal obesity (ND/AO), dynapenic/nonabdominal obesit
182 dence of an interaction between genotype and abdominal obesity on atherosclerosis and cardiovascular
183 0.004), and in participants with or without abdominal obesity (OR = 0.62, 95% CI = 0.47-0.81, Ptrend
184 e with the prevalence of NAFLD patients with abdominal obesity (OR = 0.75, 95% CI = 0.57-0.97, Ptrend
185 those with 4 births had the highest odds of abdominal obesity (OR, 2.0; 95% confidence interval, 1.5
186 related to the 20-y cumulative prevalence of abdominal obesity (P = 0.05) and high glucose (P = 0.02)
191 whether genetic predisposition to general or abdominal obesity predicts weight regain after weight lo
193 defined as the presence of three or more of: abdominal obesity, raised blood pressure, high triglycer
194 IGF-1, and metabolic syndrome abnormalities (abdominal obesity; raised A1C, blood pressure, and trigl
195 (95% CIs) for overweight or obesity and for abdominal obesity ranged from 0.63 (0.48, 0.85) to 0.40
196 21.8%) of participants with a normal BMI had abdominal obesity, ranging from 15.3% (95% CI, 15.0%-15.
197 tors of no current smoking, non-obesity, non-abdominal obesity, regular physical activity, and approp
198 ggest that studies of the gut microbiome and abdominal obesity-related disease outcomes should accoun
201 those with more than 20 years of overall and abdominal obesity, respectively, experienced progression
204 ental disorder with the cardinal features of abdominal obesity, retinopathy, polydactyly, cognitive i
205 ic analysis of MeD, stratified by gender and abdominal obesity, revealed the favorable association wa
206 ed significant evidence of selection for the abdominal obesity risk allele T of rs10494217 in Finns,
208 Hispanics/Latinas with a high prevalence of abdominal obesity suggests high risk for metabolic dysre
209 2 weeks developed the characteristics of the abdominal obesity syndrome, including insulin resistance
210 tors, a complication develops that resembles abdominal obesity syndrome, with insulin resistance and
212 ctional adipose tissue and ectopic lipids in abdominal obesity, systemic inflammation and dyslipidaem
213 s with insulin resistance, dyslipidaemia and abdominal obesity, the identification of genes for defec
214 esponse compared with casein in persons with abdominal obesity, thereby indicating a beneficial impac
215 , dyslipidaemia, diabetes or prediabetes, or abdominal obesity) to placebo, once-daily phentermine 7.
218 was linked to abdominal obesity in children (abdominal obesity vs. normal: 2.4 servings/day vs. 1.6 s
220 measures, change in overall body weight and abdominal obesity (waist circumference), and weight and
229 ver, these associations were attenuated when abdominal obesity was included in the statistical model.
230 men (body mass index, 18.5 to < 25 kg/m(2)), abdominal obesity was significantly associated with elev
231 le risk of overall obesity (BMI 30 kg/m(2)), abdominal obesity (WC>88 and 102 cm in women and men, re
232 e risk of overall obesity (BMI>=30 kg/m(2)), abdominal obesity (WC>88 and 102 cm in women and men, re
234 r CAC for each additional year of overall or abdominal obesity were 1.02 (95% CI, 1.01-1.03) and 1.03
237 differences in high-density lipoprotein and abdominal obesity were only observed in female individua
240 s of diabesity, either defined by general or abdominal obesity, were associated with increased risk o
241 esity-associated morbidity is exacerbated by abdominal obesity, which can be measured as the waist-to
243 in resistance, increased blood pressure, and abdominal obesity, which together markedly increase the
245 conducted a meta-analysis of associations of abdominal obesity with approximately 2.5 million single